Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2016 Investor Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- Wall St slides as oil hovers near $100 on rising Middle East tensions
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- Oil nears $100 as fresh Middle East strikes raise supply risks
- How big a risk are rates to the AI boom?
- 3 reasons why S&P 500 may drop up to 10% in the near term: RBC
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Mizuho Reiterates Buy Rating and $21 PT on Ironwood Pharmaceuticals (IRWD) Following 4Q16 Results
February 22, 2017 5:52 AM ESTMizuho Securities analyst Irina Koffler reiterates Buy rating and $21 price target on Ironwood Pharmaceuticals (NASDAQ: IRWD), as the company reported 2016 fourth quarter revenues and EPS figures above consensus.
Koffler comments, "4Q:16 beat was great but not surprising since consensus largely omitted a $15M milestone associated with regulatory approval in Japan: IRWD reported 4Q:16 revenues of $87.5M... More
Ironwood Pharma (IRWD) Tops Q4 EPS by 12c
February 21, 2017 4:03 PM ESTIronwood Pharma (NASDAQ: IRWD) reported Q4 EPS of ($0.12), $0.12 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $87.46 million versus the consensus estimate of $77.34 million.
2017 Financial Guidance
Ironwood expects 2017 R&D expenses to be in the range of $145... More